Pharming Group (PHGUF) Receives a Rating Update from a Top Analyst
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Pharming Group (PHGUF) today and set a price target of EUR3.10. The company’s shares closed last Monday at $1.37.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 27.4% and a 53.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Pharming Group is a Moderate Buy with an average price target of $3.65.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.82 and a one-year low of $0.83. Currently, Pharming Group has an average volume of 14K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.